Your browser doesn't support javascript.
loading
Estimating prevalence for limb-girdle muscular dystrophy based on public sequencing databases.
Liu, Wei; Pajusalu, Sander; Lake, Nicole J; Zhou, Geyu; Ioannidis, Nilah; Mittal, Plavi; Johnson, Nicholas E; Weihl, Conrad C; Williams, Bradley A; Albrecht, Douglas E; Rufibach, Laura E; Lek, Monkol.
Afiliação
  • Liu W; Program of Computational Biology and Bioinformatics, Yale University, New Haven, CT, USA.
  • Pajusalu S; Department of Genetics, Yale School of Medicine, New Haven, CT, USA.
  • Lake NJ; Department of Clinical Genetics, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.
  • Zhou G; Department of Clinical Genetics, United Laboratories, Tartu University Hospital, Tartu, Estonia.
  • Ioannidis N; Department of Genetics, Yale School of Medicine, New Haven, CT, USA.
  • Mittal P; Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Australia.
  • Johnson NE; Program of Computational Biology and Bioinformatics, Yale University, New Haven, CT, USA.
  • Weihl CC; Jain Foundation, Seattle, WA, USA.
  • Williams BA; Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA.
  • Albrecht DE; Jain Foundation, Seattle, WA, USA.
  • Rufibach LE; In-Depth Genomics, Bellevue, WA, USA.
  • Lek M; Department of Neurology, Virginia Commonwealth University, Richmond, VA, USA.
Genet Med ; 21(11): 2512-2520, 2019 11.
Article em En | MEDLINE | ID: mdl-31105274
ABSTRACT

PURPOSE:

Limb-girdle muscular dystrophies (LGMD) are a genetically heterogeneous category of autosomal inherited muscle diseases. Many genes causing LGMD have been identified, and clinical trials are beginning for treatment of some genetic subtypes. However, even with the gene-level mechanisms known, it is still difficult to get a robust and generalizable prevalence estimation for each subtype due to the limited amount of epidemiology data and the low incidence of LGMDs.

METHODS:

Taking advantage of recently published exome and genome sequencing data from the general population, we used a Bayesian method to develop a robust disease prevalence estimator.

RESULTS:

This method was applied to nine recessive LGMD subtypes. The estimated disease prevalence calculated by this method was largely comparable with published estimates from epidemiological studies; however, it highlighted instances of possible underdiagnosis for LGMD2B and 2L.

CONCLUSION:

The increasing size of aggregated population variant databases will allow for robust and reproducible prevalence estimates of recessive disease, which is critical for the strategic design and prioritization of clinical trials.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prevalence_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prevalence_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article